Indian manufacturer of medical devices such as IV cannulas, infusion sets and other disposables, with significant export sales.
Indian manufacturer of medical devices such as IV cannulas, infusion sets and other disposables, with significant export sales.
Sells high-volume disposable devices to hospitals through distributors at home and through importers abroad, and exports are a large share of sales. Hospitals use the items once and reorder, so volumes repeat. Founder Himanshu Baid leads the company.
In one line: India's smaller Becton Dickinson for disposable medical devices.
Moat: narrow (scale, regulatory licence, cost advantage). Large-scale, cost-competitive manufacturing with regulatory approvals (CE, US FDA) enabling global exports.
Headquarters: Faridabad, India · Founded: 1995 · Employees: 2,614
Size Poly Medicure (POLYMED.NS) is an India Health Care company (Medical Specialties) with a market value of $1.79B, the 411th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,654 on 18 Nov 2026.
Performance Over six months the shares gained 13.7%, against +1.5% for the median peer and +3.8% for the India market (cap-weighted) — 7th highest of 20 in its peer set.
Growth Revenue grew 24.6% over the last twelve months (peer median +9.6%); the operating margin is 16.2% (peer median 12.7%).
Valuation It trades at 39.9× forward earnings against a peer median of 25.1× (6th most expensive of 18).
Capital Return on invested capital runs 4.8 points below its cost of capital (13.6% WACC).
Next results Next results expected around 22 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹21.3B | ₹18.6B | ₹16.6B | ₹13.7B | ₹11.1B |
| Revenue growth | — | +12% | +21% | +23% | — |
| Gross profit | ₹8.50B | ₹5.36B | ₹5.10B | ₹4.07B | ₹3.00B |
| EBITDA | ₹4.84B | ₹4.52B | ₹4.52B | ₹3.61B | ₹2.71B |
| Net income | ₹3.18B | ₹3.22B | ₹3.39B | ₹2.58B | ₹1.79B |
| Free cash flow | n/a | -₹602M | -₹941M | -₹82.4M | -₹546M |
| Capital expenditure | n/a | ₹3.08B | ₹3.31B | ₹2.77B | ₹2.39B |
| Total debt | ₹4.12B | ₹3.54B | ₹1.80B | ₹1.74B | ₹1.49B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Poly Medicure POLYMED.NS | $1.79B | +14% | +25% | 16% | 39.9× | n/a |
| Becton Dickinson BDX | $58.9B | +48% | -7% | 16% | 16.3× | -1.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | POLYMED.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.7% | -5.0% | 5th highest of 21 |
| 6-month return | +13.7% | +1.5% | 7th highest of 20 |
| Distance from 52-week high | -18.3% | -24.8% | 9th highest of 21 |
| Revenue growth (TTM) | +24.6% | +9.6% | 8th highest of 21 |
| Operating margin | 16.2% | 12.7% | 9th highest of 21 |
| Forward P/E | 39.9× | 25.1× | 6th most expensive of 18 |
| ROIC minus cost of capital | -4.8 pp | +0.6 pp | 7th lowest of 21 |
| EV / EBITDA | 33.8× | 15.7× | 4th most expensive of 15 |
| Net debt / EBITDA | -0.8× | -0.7× | 7th least indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Poly Medicure POLYMED.NS | India | $1.79B | +14% | +25% | 16% | 39.9× | n/a | n/a |
| Nakanishi 7716.T | Japan | $1.78B | +7% | +17% | 21% | 19.0× | 4.8% | +19.7% |
| ChemoMetec A/S CHEMM.CO | Denmark | $1.77B | +107% | +3% | 49% | 46.7× | 19.4% | +12.7% |
| Shandong Weigao Group Medical Polymer 1066.HK | Hong Kong | $1.82B | -8% | +7% | 14% | 8.2× | -12.6% | +2.1% |
| Fukuda Denshi 6960.T | Japan | $1.84B | +4% | 0% | 19% | 15.4× | -1.6% | -1.0% |
| Rigaku 268A.T | Japan | $1.85B | -54% | +9% | 16% | 23.1× | 18.3% | +14.5% |
| Molbio Diagnostics MOLBIO.NS | India | $1.85B | n/a | +35% | 17% | n/a | n/a | n/a |
| SKAN SKAN.SW | Switzerland | $1.85B | +40% | +9% | 11% | 49.5× | 13.8% | +11.7% |
| Medartis MED.SW | Switzerland | $1.86B | +47% | +30% | 2% | 72.8× | n/a | n/a |
| LeMaitre Vascular LMAT | United States | $1.73B | -25% | +12% | 28% | 24.5× | 2.9% | +14.0% |
| Mehow Innovative 301363.SZ | China | $1.72B | -36% | +10% | 21% | 34.2× | 16.4% | +12.9% |
| Embla Medical hf EMBLA.CO | Denmark | $1.72B | +1% | +6% | 14% | 17.2× | -1.9% | +8.3% |
| DENTSPLY SIRONA XRAY | United States | $1.69B | -13% | -1% | 5% | 6.8× | 11.2% | +1.9% |
| Kestra Medical Technologies KMTS | United States | $1.69B | +36% | +61% | -134% | n/a | n/a | n/a |
| Inspire Medical Systems INSP | United States | $1.68B | +32% | 0% | 2% | 41.3× | 28.7% | +51.2% |
| NIPRO 8086.T | Japan | $1.68B | -11% | +5% | 5% | 15.8× | n/a | n/a |
| Butterfly Network BFLY | United States | $1.63B | +38% | +39% | -36% | n/a | n/a | n/a |
| Angelalign Technology 6699.HK | Hong Kong | $1.62B | -8% | +84% | 9% | 52.5× | 16.7% | +25.8% |
| Cofoe Medical Technology 301087.SZ | China | $1.60B | -6% | +33% | 10% | 25.1× | 11.2% | +7.4% |
| Wuxi Unicomp Technology 688531.SS | China | $1.58B | -49% | +53% | 12% | 35.8× | n/a | n/a |
| Vitrolife VITR.ST | Sweden | $1.57B | +13% | -2% | 19% | 27.0× | 22.2% | +22.5% |